{"id":60062,"date":"2026-03-19T23:32:23","date_gmt":"2026-03-19T15:32:23","guid":{"rendered":"https:\/\/flcube.com\/?p=60062"},"modified":"2026-03-19T23:32:24","modified_gmt":"2026-03-19T15:32:24","slug":"huahai-pharmaceutical-initiates-phase-iii-trial-for-hb0025-pd-l1-vegf-bispecific-targets-first-line-endometrial-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60062","title":{"rendered":"Huahai Pharmaceutical Initiates Phase III Trial for HB0025 \u2013 PD-L1\/VEGF Bispecific Targets First-Line Endometrial Cancer"},"content":{"rendered":"\n

Zhejiang Huahai Pharmaceutical Co., Ltd.<\/strong> (SHA: 600521<\/a>) announced the initiation of a Phase III clinical trial<\/strong> evaluating HB0025 in combination with chemotherapy<\/strong> for the first-line treatment of advanced or recurrent endometrial cancer<\/strong>. The in-house developed anti-PD-L1\/VEGF bispecific fusion protein<\/strong> represents Huahai’s entry into the dual-target immuno-oncology space<\/strong>, leveraging synergistic “immune enhancement + anti-angiogenesis”<\/strong> mechanisms.<\/p>\n\n\n\n

Clinical Trial Overview<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Phase<\/strong><\/td>Phase III (pivotal)<\/td><\/tr>
Treatment Regimen<\/strong><\/td>HB0025 + chemotherapy combination<\/td><\/tr>
Indication<\/strong><\/td>Advanced or recurrent endometrial cancer (first-line)<\/td><\/tr>
Line of Therapy<\/strong><\/td>First-line (treatment-na\u00efve or early recurrent)<\/td><\/tr>
Developer<\/strong><\/td>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)<\/td><\/tr>
Announcement Date<\/strong><\/td>19\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>HB0025 Specification<\/th><\/tr><\/thead>
Format<\/strong><\/td>Anti-PD-L1\/VEGF bispecific fusion protein<\/strong><\/td><\/tr>
Target 1<\/strong><\/td>PD-L1<\/strong> \u2013 blocks tumor immune evasion pathway<\/td><\/tr>
Target 2<\/strong><\/td>VEGF<\/strong> \u2013 inhibits tumor angiogenesis<\/td><\/tr>
Binding Affinity<\/strong><\/td>High-affinity binding to both targets simultaneously<\/td><\/tr>
Mechanism<\/strong><\/td>Dual antitumor action:<\/strong> immune enhancement + anti-angiogenesis<\/td><\/tr>
Therapeutic Strategy<\/strong><\/td>Synergistic modulation of tumor immune microenvironment and vascular normalization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Landscape<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Endometrial Cancer Incidence<\/strong><\/td>~80,000 new cases annually<\/strong> in China; rising with obesity\/diabetes trends; 15\u201320% advanced\/metastatic<\/strong> at diagnosis<\/td><\/tr>
First-Line Standard<\/strong><\/td>Carboplatin\/paclitaxel + pembrolizumab (PD-1) for MMR-deficient; limited options for MMR-proficient patients<\/td><\/tr>
PD-1\/VEGF Rationale<\/strong><\/td>Validated by lenvatinib\/pembrolizumab<\/strong> in endometrial cancer (KEYNOTE-775); HB0025 offers single-molecule convenience<\/strong> vs. combination<\/td><\/tr>
Bispecific Advantage<\/strong><\/td>Coordinated pharmacokinetics; reduced dosing complexity; potential for improved safety profile<\/strong> vs. small molecule TKIs + ICI combinations<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Akesobio (PD-1\/VEGF, Phase II), Sino Biopharm (PD-L1\/VEGF, preclinical); Huahai aims for first-to-market bispecific<\/strong> in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Strategy & Market Impact<\/h2>\n\n\n\n
Initiative<\/th>Strategic Value<\/th><\/tr><\/thead>
First-Line Positioning<\/strong><\/td>Captures largest addressable population before resistance develops<\/td><\/tr>
Chemotherapy Combination<\/strong><\/td>Standard backbone enables pragmatic trial design<\/strong> and regulatory familiarity<\/strong><\/td><\/tr>
MMR-Agnostic Potential<\/strong><\/td>Dual mechanism may benefit both MMR-deficient (PD-1 responsive) and MMR-proficient (angiogenesis-dependent) subtypes<\/td><\/tr>
Global Rights<\/strong><\/td>Huahai retains worldwide rights; potential for ex-China partnership<\/strong> post-China Phase III data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n